Pharma Industry News
Printable Version   Email to a friend

Medicare's Prescription Drug Plan Enrollment Deadline Looms

Medicare's Prescription Drug Plan Enrollment Deadline Looms

December 27, 2006 -- The deadline for enrolling in or changing your Medicare prescription drug plan is fast approaching, and experts agree that you need to choose carefully because premiums have increased and drug coverage has changed in many plans.

"In terms of premium increases, 77 percent of drug plan enrollees are in plans where premiums will be increasing," said Larry Levitt, a vice president at the Kaiser Family Foundation. The deadline for picking a plan for 2007 is Dec. 31, and that decision can't be changed again until next November.

However, if a recent survey holds true, many seniors will simply stick with what they've got.

According to a report by the Kaiser Family Foundation and the Harvard University School of Public Health, only 5 percent of those currently enrolled in a Medicare prescription drug plan say they expect to switch plans for 2007. Overall, 76 percent of people enrolled in a plan say that their experiences have been positive, and 46 percent say they have been "very positive." Fifty-two percent say they are saving money with their drug plan, while 14 percent say they are paying more.

On the downside, 23 percent say they have had a problem with the new benefit, and, for 12 percent, it was a major problem. In addition, 73 percent say the Medicare drug benefit is "too complicated," and 39 percent say there are too many plans offered.

One expert says that people planning to enroll in a drug plan need to evaluate all the plans to find the one that is best for them.

"If you are dealing with having to make a decision on a Medicare prescription drug plan, you have to use the computer to get to the drug plan finder," said Esther Koch, from Encore Management, a company that helps Medicare patients select plans. For seniors who are not computer-savvy, Koch recommends they get their children to help them.

The drug plan finder will estimate the total annual cost for each plan, including the premium, the deductible, the co-pay and the coinsurance, Koch said. "The plans are sorted from least expensive to most expensive," she said. "The finder will also tell you how your drug benefit will be covered in the 'donut hole.' "

The "donut hole" refers to a period where after total drug costs reach $2,250, participants will pay an additional $2,850 out-of-pocket before Medicare Part D will continue coverage. This coverage gap is called the "donut hole." After this point, Medicare pays for 95 percent of drug costs, and participants would pay the remaining 5 percent.

To find the right plan, people need to contact Medicare or use the plan finder, said Deane Beebe, communications director at the Medicare Rights Center. "Once you find out which plan might be best, call the plan and verify all the information you got from Medicare before you enroll," she said. "What you see and hear from Medicare is not always consistent with what the plan is actually offering. You must double-check."

Koch also believes that people should review the plans annually and not just stay in the same plan. "The plans are going to change. The drugs are going to change," she said. "It's unfortunate that only 5 percent say they are going to change plans."

Beebe also thinks it is essential for current enrollees to look at their choices again and not automatically continue with their current plan.

"Anybody who signed up for a plan last year must take a close look to see if their current plan is likely to meet their needs in 2007," Beebe said. "No one is free of having to go back and sort this all out all over again," she said. "This is important because people are going to be locked into their plan until the end of 2007."

Beebe noted that although all the plans are supposed to notify people of changes, these changes are not always easy to understand. "It's a sad fact that people are not aware that plans are changing," she said.

Levitt also thinks that people currently enrolled in a plan should reevaluate it. "The plans change, and people's circumstances change, so it's not necessarily the right decision for everyone to stick with their plan," he said.

For more information visit Medicare - www.medicare.gov

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


MedNotes
Latest FDA Drug Alerts
October 7, 2008
Audience: Pulmonary care health professionals and patients[UPDATE 10/07/2008] FDA informed healthcare professionals that FDA has...
October 3, 2008
Audience: Healthcare professionals, consumers [Posted 10/03/2008] FDA notified healthcare professionals of a Class I Recall of...
October 2, 2008
Audience: Physical medicine and rehabilitation specialists, anesthesia healthcare professionals, hospital surgical service...
September 30, 2008
Audience: Neurologists, cardiologists, consumers[Posted 09/30/2008] An FDA analysis provides new evidence that the use of statins...
More...
Latest Drug Information Updates

AdreView
AdreView is a diagnostic radiopharmaceutical agent indicated for use in the detection of rare neuroendocrine tumors in children and adults.

Sancuso
Sancuso (granisetron transdermal system) is an anti-emetic transdermal delivery system indicated for the control of nausea and vomiting in patients receiving moderately and/or highly nausea-inducing chemotherapy.

Nplate
Nplate (romiplostim) is a thrombopoietin mimetic peptibody for the treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP).

Xenazine
Xenazine (tetrabenazine) is a selective and reversible centrally-acting dopamine depleting drug indicated for the treatment of chorea associated with Huntington's disease.

Cleviprex
Cleviprex is an intravenous, ultrashort-acting calcium channel blocker under development for the treatment of severely elevated blood pressure in the hospital setting when oral therapy is not feasible or desirable.

Stavzor
Stavzor is delayed-release valproic acid formulated in the EnteriCare enteric soft gelatin capsule delivery system designed to minimize GI adverse events. Stavzor is indicated for the treatment of manic episodes associated with bipolar disorder, adjunctive therapy in multiple seizure types (including epilepsy), and prophylaxis of migraine headaches.

Navstel
Navstel is a balanced salt ophthalmic solution for use as an intraocular irrigation during surgical procedures involving perfusion of the eye.

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

More...